[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:histiocytic-and-dendritic-cell-neoplasm":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":35,"states":36},"Histiocytic and Dendritic Cell Neoplasm",4,[7,15,22,29],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06411821","Ulixertinib in People With Histiocytic Neoplasms",[11],"Phase 2","RECRUITING","2026-08-26T02:17:05.997056Z","2026-07-05T05:32:16.753306Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03017820","A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",[19],"Phase 1","2026-08-26T02:19:05.360997Z","2026-06-16T05:54:07.906191Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[26],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT03329274","Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses",[],"2026-08-26T02:17:19.710918Z","2026-05-13T02:55:06.121404Z",[],[]]